These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18997134)

  • 1. Hiccups and dopamine.
    Stegmeier-Petroianu A; Petroianu GA
    Am J Health Syst Pharm; 2008 Nov; 65(22):2092-4. PubMed ID: 18997134
    [No Abstract]   [Full Text] [Related]  

  • 2. Hiccups in Parkinson's disease: an analysis of cases reported in the European pharmacovigilance database and a review of the literature.
    Lertxundi U; Marquínez AC; Domingo-Echaburu S; Solinís MÁ; Calvo B; Del Pozo-Rodríguez A; García M; Aguirre C; Isla A
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1159-1164. PubMed ID: 28600702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hiccups associated with non-ergoline dopamine agonists in Parkinson's disease.
    Coletti Moja M
    Mov Disord; 2010 Jul; 25(9):1292. PubMed ID: 20310014
    [No Abstract]   [Full Text] [Related]  

  • 4. Perphenazine-induced hiccups.
    Miyaoka H; Kamijima K
    Pharmacopsychiatry; 1999 Mar; 32(2):81. PubMed ID: 10333169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hiccups associated with dopamine agonists in Parkinson disease.
    Sharma P; Morgan JC; Sethi KD
    Neurology; 2006 Mar; 66(5):774. PubMed ID: 16534128
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine agonists in early therapy for Parkinson disease: promise and problems.
    Tanner CM
    JAMA; 2000 Oct; 284(15):1971-3. PubMed ID: 11035895
    [No Abstract]   [Full Text] [Related]  

  • 7. Alopecia induced by dopamine agonists.
    Tabamo RE; Di Rocco A
    Neurology; 2002 Mar; 58(5):829-30. PubMed ID: 11889256
    [No Abstract]   [Full Text] [Related]  

  • 8. Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone?
    Fernandez HH; Merello M
    Lancet Neurol; 2010 Jun; 9(6):556-7. PubMed ID: 20452824
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.
    Kovacs N; Janszky J; Nagy F
    Drugs Aging; 2011 Feb; 28(2):161-2. PubMed ID: 21275441
    [No Abstract]   [Full Text] [Related]  

  • 10. Pramipexole and somnolence.
    Shuster J
    Nursing; 2000 Aug; 30(8):81. PubMed ID: 10983129
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG; Togrol RE
    Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract]   [Full Text] [Related]  

  • 12. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New dopaminergic agonists].
    de Mattos JP; Mattos VM
    Arq Neuropsiquiatr; 1999 Jun; 57(2A):329-32. PubMed ID: 10412541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease.
    Barboi AC; Goetz CG
    Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment in Parkinson disease].
    Takáts A
    Orv Hetil; 2004 Apr; 145(15):833-4. PubMed ID: 15188639
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term retention rate of pramipexole in the treatment of Parkinson's disease.
    Keränen T; Tuhkasaari M; Kuusisto H
    Eur J Clin Pharmacol; 2009 Sep; 65(9):955-6; author reply 957. PubMed ID: 19415250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.